Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYX NASDAQ:PLSE NASDAQ:VERO NASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$3.67+3.1%$3.63$1.08▼$4.50$153.52M1.35150,202 shs256,333 shsPLSEPulse Biosciences$19.08-2.6%$20.85$12.56▼$26.30$1.30B1.63310,522 shs201,685 shsVEROVenus Concept$0.31$0.33$0.25▼$12.93$442K-0.062.28 million shsN/AXAIRBeyond Air$0.51+3.2%$0.70$0.43▼$5.84$6.77M0.35.35 million shs241,273 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical+21.92%+6.91%-5.07%-8.25%+184.80%PLSEPulse Biosciences+1.98%-7.46%-1.85%-5.59%+17.31%VEROVenus Concept0.00%0.00%+0.00%-72.76%-86.73%XAIRBeyond Air-12.00%-5.33%-29.97%-56.77%-86.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$3.67+3.1%$3.63$1.08▼$4.50$153.52M1.35150,202 shs256,333 shsPLSEPulse Biosciences$19.08-2.6%$20.85$12.56▼$26.30$1.30B1.63310,522 shs201,685 shsVEROVenus Concept$0.31$0.33$0.25▼$12.93$442K-0.062.28 million shsN/AXAIRBeyond Air$0.51+3.2%$0.70$0.43▼$5.84$6.77M0.35.35 million shs241,273 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical+21.92%+6.91%-5.07%-8.25%+184.80%PLSEPulse Biosciences+1.98%-7.46%-1.85%-5.59%+17.31%VEROVenus Concept0.00%0.00%+0.00%-72.76%-86.73%XAIRBeyond Air-12.00%-5.33%-29.97%-56.77%-86.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 2.67Moderate Buy$6.5077.11% UpsidePLSEPulse Biosciences 2.33Hold$30.0057.23% UpsideVEROVenus Concept 1.00SellN/AN/AXAIRBeyond Air 2.33Hold$10.001,849.32% UpsideCurrent Analyst Ratings BreakdownLatest PLSE, XAIR, VERO, and APYX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026XAIRBeyond Air Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PLSEPulse Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026APYXApyx Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026XAIRBeyond Air D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/18/2026XAIRBeyond Air D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/11/2026APYXApyx Medical Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $6.003/11/2026APYXApyx Medical BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.003/10/2026XAIRBeyond Air D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.002/20/2026PLSEPulse Biosciences OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$30.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$52.84M2.91N/AN/A$0.39 per share9.41PLSEPulse Biosciences$751K1,733.33N/AN/A$1.19 per share16.03VEROVenus Concept$58.88M0.01N/AN/A$4.30 per share0.07XAIRBeyond Air$6.92M0.98N/AN/A$3.32 per share0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$11.21M-$0.27N/AN/AN/A-21.22%-114.95%-18.49%N/APLSEPulse Biosciences-$72.78M-$1.10N/AN/AN/AN/A-80.51%-69.14%N/AVEROVenus Concept-$47M-$48.84N/AN/AN/A-92.76%-1,904.25%-85.22%N/AXAIRBeyond Air-$46.62M-$5.43N/AN/AN/A-447.75%-268.82%-98.49%6/29/2026 (Estimated)Latest PLSE, XAIR, VERO, and APYX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026APYXApyx Medical-$0.11-$0.05+$0.06-$0.05$10.78 million$12.49 million5/4/2026Q1 2026PLSEPulse Biosciences-$0.32-$0.27+$0.05-$0.27$0.25 million$0.40 million3/10/2026Q4 2025APYXApyx Medical-$0.06-$0.03+$0.03-$0.03$19.12 million$19.16 million2/19/2026Q4 2025PLSEPulse Biosciences-$0.32-$0.26+$0.06-$0.26$0.23 millionN/A2/13/2026Q3 2026XAIRBeyond Air-$0.54-$0.85-$0.31-$0.85$2.15 million$2.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/APLSEPulse BiosciencesN/AN/AN/AN/AN/AVEROVenus ConceptN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical2.355.004.26PLSEPulse BiosciencesN/A10.5310.51VEROVenus Concept1.590.900.59XAIRBeyond Air2.655.124.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%PLSEPulse Biosciences76.95%VEROVenus Concept87.41%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical15.20%PLSEPulse Biosciences74.60%VEROVenus Concept28.04%XAIRBeyond Air17.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27041.83 million35.47 millionOptionablePLSEPulse Biosciences14068.23 million17.33 millionOptionableVEROVenus Concept4101.42 million1.03 millionNot OptionableXAIRBeyond Air7013.19 million10.95 millionOptionablePLSE, XAIR, VERO, and APYX HeadlinesRecent News About These CompaniesBeyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026April 20, 2026 | globenewswire.comLucid, Beyond Air, Conagra stocks hit 52-week lows: What's behind the drag?April 16, 2026 | msn.comBeyond Air Appeals Nasdaq Notice on Listing ComplianceApril 15, 2026 | tipranks.comBeyond Air to Participate in the D. Boral Capital Global Conference 2026April 15, 2026 | globenewswire.comBeyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)April 1, 2026 | markets.businessinsider.comBeyond Air Names Robert Goodman as New CEOApril 1, 2026 | tipranks.comBeyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEOMarch 26, 2026 | markets.businessinsider.comBeyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO TrialMarch 17, 2026 | globenewswire.comBeyond Air to Participate in the 38th Annual Roth Conference in MarchMarch 11, 2026 | markets.businessinsider.comBeyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.March 10, 2026 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA) and Beyond Air (XAIR)March 8, 2026 | theglobeandmail.comBeyond Air Inc (XAIR) Expands Focus on Nitric Oxide TherapiesMarch 4, 2026 | finance.yahoo.comHow The Narrative On Beyond Air (XAIR) Is Resetting Around LungFit PH And Delayed ApprovalFebruary 26, 2026 | finance.yahoo.comBeyond Air Inc (XAIR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth and Strategic ...February 21, 2026 | finance.yahoo.comBeyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating ...February 20, 2026 | finance.yahoo.comBeyond Air, Inc. Highlights Comprehensive Review on High-Dose Inhaled Nitric Oxide as Potential Antimicrobial Therapy for Respiratory InfectionsFebruary 20, 2026 | quiverquant.comQBeyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory InfectionsFebruary 20, 2026 | globenewswire.comBeyond Air, Inc. Q3 2026 Earnings Call SummaryFebruary 14, 2026 | finance.yahoo.comBeyond Air, Inc. (NASDAQ:XAIR) Q3 2026 earnings call transcriptFebruary 14, 2026 | msn.comBeyond Air XAIR Q3 2026 Earnings Call TranscriptFebruary 13, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePLSE, XAIR, VERO, and APYX Company DescriptionsApyx Medical NASDAQ:APYX$3.67 +0.11 (+3.09%) Closing price 04:00 PM EasternExtended Trading$3.67 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Pulse Biosciences NASDAQ:PLSE$19.08 -0.51 (-2.60%) Closing price 04:00 PM EasternExtended Trading$19.09 +0.01 (+0.05%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.Venus Concept NASDAQ:VERO$0.31 0.00 (0.00%) As of 05/7/2026Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.Beyond Air NASDAQ:XAIR$0.51 +0.02 (+3.18%) Closing price 04:00 PM EasternExtended Trading$0.50 -0.01 (-1.56%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
